{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:45:52Z","timestamp":1793241952556,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1120816N"],"award-info":[{"award-number":["1120816N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Papillomavirus Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.pvr.2019.100185","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T12:29:10Z","timestamp":1567686550000},"page":"100185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature"],"prefix":"10.1016","volume":"8","author":[{"given":"Jade","family":"Pattyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severien","family":"Van Keer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebren","family":"Tjalma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Matheeussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Vorsters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.pvr.2019.100185_bib2","series-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin in","author":"Bray","year":"2018"},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.virol.2008.10.004","article-title":"Interaction of human papillomaviruses with the host immune system: a well evolved relationship","volume":"384","author":"Frazer","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.pvr.2019.100185_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-9378-5-19","article-title":"HPV - immune response to infection and vaccination","volume":"5","author":"Stanley","year":"2010","journal-title":"Infect. Agents Cancer"},{"issue":"7","key":"10.1016\/j.pvr.2019.100185_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jnci\/djn044","article-title":"Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections","volume":"100","author":"Rodriguez","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl 1","key":"10.1016\/j.pvr.2019.100185_bib6","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.pvr.2019.100185_bib7","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri1260","article-title":"Prevention of cervical cancer through papillomavirus vaccination","volume":"4","author":"Frazer","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.pvr.2019.100185_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1386-6532(00)00091-3","article-title":"Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report","volume":"19","author":"Schiller","year":"2000","journal-title":"J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol."},{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"issue":"9580","key":"10.1016\/j.pvr.2019.100185_bib11","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.pvr.2019.100185_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nri2967","article-title":"Antibody responses: FcRn-not just for the kids","volume":"11","author":"Bordon","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.pvr.2019.100185_bib13","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1073\/pnas.1012861108","article-title":"Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection","volume":"108","author":"Li","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"Suppl 3","key":"10.1016\/j.pvr.2019.100185_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.vaccine.2006.05.110","article-title":"Chapter 12: prophylactic HPV vaccines: underlying mechanisms","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"10.1016\/j.pvr.2019.100185_bib15","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines--immune responses","volume":"30","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2019.100185_bib16","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"Suppl 1","key":"10.1016\/j.pvr.2019.100185_bib17","first-page":"S1","article-title":"The epidemiology of genital human papillomavirus infection","volume":"24","author":"Trottier","year":"2006","journal-title":"Vaccine"},{"issue":"3 Suppl 1","key":"10.1016\/j.pvr.2019.100185_bib18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2008.05.036","article-title":"Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16\/18 vaccine: improving upon nature","volume":"110","author":"Schwarz","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"3 Suppl 1","key":"10.1016\/j.pvr.2019.100185_bib19","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/j.ygyno.2005.07.100","article-title":"Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study","volume":"99","author":"Bierl","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"Pt 2","key":"10.1016\/j.pvr.2019.100185_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1099\/0022-1317-80-2-409","article-title":"Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16","volume":"80","author":"Bontkes","year":"1999","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ijc.2910430109","article-title":"Detection of IgA antibodies against human papillomavirus in cervical secretions from patients with cervical intraepithelial neoplasia","volume":"43","author":"Dillner","year":"1989","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1128\/jcm.31.2.192-197.1993","article-title":"Antibodies against papillomavirus antigens in cervical secretions from condyloma patients","volume":"31","author":"Dillner","year":"1993","journal-title":"J. Clin. Microbiol."},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0028-2243(95)02049-X","article-title":"Seric and local antibodies against a synthetic peptide of HPV16","volume":"59","author":"Dreyfus","year":"1995","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"10","key":"10.1016\/j.pvr.2019.100185_bib24","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.7314\/APJCP.2014.15.10.4197","article-title":"Local cervical immunity in women with low-grade squamous intraepithelial lesions and immune responses after abrasion","volume":"15","author":"Ekalaksananan","year":"2014","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"3","key":"10.1016\/j.pvr.2019.100185_bib25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0002-9378(96)70330-7","article-title":"Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens","volume":"174","author":"Elfgren","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.pvr.2019.100185_bib26","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/315364","article-title":"Detection of cervical antibodies to human papillomavirus type 16 (HPV-P6) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions","volume":"181","author":"Hagensee","year":"2000","journal-title":"JID (J. Infect. Dis.)"},{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/CVI.00118-07","article-title":"Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies","volume":"15","author":"Kemp","year":"2008","journal-title":"Clin. Vaccine Immunol. : CVI"},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1574-695X.2008.00484.x","article-title":"Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients","volume":"54","author":"Lopez","year":"2008","journal-title":"FEMS Immunol. Med. Microbiol."},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jmv.21343","article-title":"HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers","volume":"81","author":"Marais","year":"2009","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.pvr.2019.100185_bib30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1086\/315815","article-title":"The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions","volume":"182","author":"Marais","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pvr.2019.100185_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1099\/vir.0.83458-0","article-title":"Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease","volume":"89","author":"Mbulawa","year":"2008","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcv.2009.10.008","article-title":"Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy","volume":"47","author":"Monroy","year":"2010","journal-title":"J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol."},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2004.10.019","article-title":"Immune responses to human papillomavirus in genital tract of women with cervical cancer","volume":"96","author":"Nguyen","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0042-6822(03)00196-X","article-title":"Characterization of IgA response among women with incident HPV 16 infection","volume":"312","author":"Onda","year":"2003","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.pvr.2019.100185_bib35","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/jmv.20901","article-title":"Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia","volume":"79","author":"Passmore","year":"2007","journal-title":"J. Med. Virol."},{"issue":"Pt 9","key":"10.1016\/j.pvr.2019.100185_bib36","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1099\/vir.0.80077-0","article-title":"Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions","volume":"85","author":"Rocha-Zavaleta","year":"2004","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/088282403322017893","article-title":"Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology","volume":"16","author":"Rocha-Zavaleta","year":"2003","journal-title":"Viral Immunol."},{"issue":"3","key":"10.1016\/j.pvr.2019.100185_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ijc.10939","article-title":"Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids","volume":"104","author":"Sasagawa","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"1\u20132","key":"10.1016\/j.pvr.2019.100185_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-1759(02)00038-8","article-title":"Comparative analysis of methods for collection and measurement of cytokines and immunoglobulins in cervical and vaginal secretions of HIV and HPV infected women","volume":"263","author":"Snowhite","year":"2002","journal-title":"J. Immunol. Methods"},{"issue":"16","key":"10.1016\/j.pvr.2019.100185_bib40","first-page":"4423","article-title":"Binding by immunoglobulin to the HPV-16-derived proteins L1 and E4 in cervical secretions of women with HPV-related cervical disease","volume":"51","author":"Snyder","year":"1991","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.pvr.2019.100185_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1525-1438.2000.010004296.x","article-title":"IgG antibodies against human papillomavirus type 16 E7 proteins in cervicovaginal washing fluid from patients with cervical neoplasia","volume":"10","author":"Tjiong","year":"2000","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.pvr.2019.100185_bib42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/08828240152716655","article-title":"Antibodies against human papillomavirus type 16 and 18 E6 and E7 proteins in cervicovaginal washings and serum of patients with cervical neoplasia","volume":"14","author":"Tjiong","year":"2001","journal-title":"Viral Immunol."},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jmv.1890430219","article-title":"Human papillomavirus DNA and anti-HPV secretory IgA antibodies in cytologically normal cervical specimens","volume":"43","author":"Veress","year":"1994","journal-title":"J. Med. Virol."},{"issue":"12","key":"10.1016\/j.pvr.2019.100185_bib44","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1128\/jcm.34.12.3056-3062.1996","article-title":"Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA","volume":"34","author":"Wang","year":"1996","journal-title":"J. Clin. Microbiol."},{"issue":"5","key":"10.1016\/j.pvr.2019.100185_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jnci\/djh071","article-title":"Re: specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles","volume":"96","author":"Barr","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.pvr.2019.100185_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061825","article-title":"A randomized, observer-blinded immunogenicity trial of Cervarix((R)) and Gardasil((R)) Human Papillomavirus vaccines in 12-15 year old girls","volume":"8","author":"Draper","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.pvr.2019.100185_bib47","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccine"},{"issue":"12","key":"10.1016\/j.pvr.2019.100185_bib48","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum. Vaccine"},{"issue":"12","key":"10.1016\/j.pvr.2019.100185_bib49","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.4161\/hv.36117","article-title":"Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"issue":"21\u201322","key":"10.1016\/j.pvr.2019.100185_bib50","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2003.11.058","article-title":"Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women","volume":"22","author":"Fife","year":"2004","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.pvr.2019.100185_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/OLQ.0000000000000429","article-title":"Characterization of immunoglobulin A\/G responses during 3 doses of the human papillomavirus-16\/18 ASO4-adjuvanted vaccine","volume":"43","author":"Goncalves","year":"2016","journal-title":"Sex. Transm. Dis."},{"issue":"3","key":"10.1016\/j.pvr.2019.100185_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033736","article-title":"Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers","volume":"7","author":"Huo","year":"2012","journal-title":"PLoS One"},{"issue":"29\u201330","key":"10.1016\/j.pvr.2019.100185_bib53","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1016\/j.vaccine.2008.04.074","article-title":"Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women","volume":"26","author":"Kemp","year":"2008","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.pvr.2019.100185_bib54","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1016\/j.vaccine.2005.02.019","article-title":"Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine","volume":"23","author":"Nardelli-Haefliger","year":"2005","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.pvr.2019.100185_bib55","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djg018","article-title":"Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles","volume":"95","author":"Nardelli-Haefliger","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.pvr.2019.100185_bib56","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.25887","article-title":"Long-term persistence of systemic and mucosal immune response to HPV-16\/18 AS04-adjuvanted vaccine in preteen\/adolescent girls and young women","volume":"129","author":"Petaja","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib57","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/hv.22693","article-title":"Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination","volume":"9","author":"Scherpenisse","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/1471-0528.13070","article-title":"Persistence of immune responses to the HPV-16\/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study","volume":"122","author":"Schwarz","year":"2015","journal-title":"BJOG An Int. J. Obstet. Gynaecol."},{"issue":"11","key":"10.1016\/j.pvr.2019.100185_bib59","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cam4.1155","article-title":"Ten-year immune persistence and safety of the HPV-16\/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age","volume":"6","author":"Schwarz","year":"2017","journal-title":"Cancer medicine"},{"issue":"12","key":"10.1016\/j.pvr.2019.100185_bib60","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4161\/hv.6.12.13399","article-title":"Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine","volume":"6","author":"Schwarz","year":"2010","journal-title":"Hum. Vaccine"},{"issue":"4","key":"10.1016\/j.pvr.2019.100185_bib61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2008.10.088","article-title":"Immunogenicity and tolerability of an HPV-16\/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.pvr.2019.100185_bib62","first-page":"2313","article-title":"Immune response to human papillomavirus one year after prophylactic vaccination with AS04-adjuvanted HPV-16\/18 vaccine: HPV-specific IgG and IgA antibodies in the circulation and the cervix","volume":"19","author":"Ferreira Costa","year":"2018","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1128\/CMR.05028-11","article-title":"Epithelial cell responses to infection with human papillomavirus","volume":"25","author":"Stanley","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"issue":"10","key":"10.1016\/j.pvr.2019.100185_bib64","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1128\/JVI.72.10.8220-8229.1998","article-title":"Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions","volume":"72","author":"Balmelli","year":"1998","journal-title":"J. Virol."},{"issue":"14","key":"10.1016\/j.pvr.2019.100185_bib65","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.vaccine.2010.01.013","article-title":"Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants","volume":"28","author":"Cho","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.pvr.2019.100185_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074797","article-title":"Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses","volume":"8","author":"Scherpenisse","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.pvr.2019.100185_bib68","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1128\/iai.62.9.3957-3961.1994","article-title":"Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination","volume":"62","author":"Bouvet","year":"1994","journal-title":"Infect. Immun."},{"issue":"24","key":"10.1016\/j.pvr.2019.100185_bib69","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1128\/JVI.06093-11","article-title":"A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection","volume":"85","author":"Longet","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-1759(97)00003-3","article-title":"Comparative analysis of methods for collection and measurement of immunoglobulins in cervical and vaginal secretions of women","volume":"202","author":"Quesnel","year":"1997","journal-title":"J. Immunol. Methods"},{"issue":"2","key":"10.1016\/j.pvr.2019.100185_bib71","first-page":"399","article-title":"Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions","volume":"11","author":"Castle","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"4","key":"10.1016\/j.pvr.2019.100185_bib72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/CDLI.5.4.491-493.1998","article-title":"Collection of cervical secretions does not adversely affect Pap smears taken immediately afterward","volume":"5","author":"Hildesheim","year":"1998","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.pvr.2019.100185_bib73","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-1759(99)00037-X","article-title":"Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures","volume":"225","author":"Hildesheim","year":"1999","journal-title":"J. Immunol. Methods"},{"issue":"7","key":"10.1016\/j.pvr.2019.100185_bib74","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/QAD.0000000000001038","article-title":"Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women","volume":"30","author":"Mkhize","year":"2016","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.pvr.2019.100185_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcv.2019.05.004","article-title":"First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions","volume":"117","author":"Van Keer","year":"2019","journal-title":"J. Clin. Virol.: Off. publ. Pan Am. Soc. Clin. Virol."},{"issue":"32 Pt A","key":"10.1016\/j.pvr.2019.100185_bib76","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"Pinto","year":"2018","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.pvr.2019.100185_bib77","doi-asserted-by":"crossref","first-page":"S470","DOI":"10.1086\/314806","article-title":"Mucosal immune system of the human genital tract","volume":"179","author":"Mestecky","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.pvr.2019.100185_bib78","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0897.2005.00267.x","article-title":"Immunologic uniqueness of the genital tract: challenge for vaccine development","volume":"53","author":"Mestecky","year":"2005","journal-title":"Am. J. Reprod. Immunol."},{"issue":"1","key":"10.1016\/j.pvr.2019.100185_bib79","first-page":"1","article-title":"Immune aspects of female infertility","volume":"10","author":"Brazdova","year":"2016","journal-title":"Int J Fertil Steril"},{"key":"10.1016\/j.pvr.2019.100185_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30279-8","article-title":"Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial","author":"Abraham","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Papillomavirus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852119300655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852119300655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:04:28Z","timestamp":1762513468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405852119300655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":80,"alternative-id":["S2405852119300655"],"URL":"https:\/\/doi.org\/10.1016\/j.pvr.2019.100185","relation":{},"ISSN":["2405-8521"],"issn-type":[{"value":"2405-8521","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature","name":"articletitle","label":"Article Title"},{"value":"Papillomavirus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pvr.2019.100185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100185"}}